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Celiac disease (CD) is an immune-mediated enteropathy that develops in genetically susceptible individuals following exposure
to dietary gluten. Severe changes at the intestinal mucosa observed in untreated CD patients are linked to changes in the level
and in the pattern of expression of different genes. Fully differentiated epithelial cells express two isoforms of fatty acid binding
proteins (FABPs): intestinal and liver, IFABP and LFABP, respectively. These proteins bind and transport long chain fatty acids and
also have other important biological roles in signaling pathways, particularly those related to PPAR𝛾 and inflammatory processes.
Herein, we analyze the serum levels of IFABP and characterize the expression of both FABPs at protein and mRNA level in small
intestinal mucosa in severe enteropathy and normal tissue. As a result, we observed higher levels of circulating IFABP in untreated
CD patients compared with controls and patients on gluten-free diet. In duodenal mucosa a differential FABPs expression pattern
was observed with a reduction in mRNA levels compared to controls explained by the epithelium loss in severe enteropathy. In
conclusion, we report changes in FABPs’ expression pattern in severe enteropathy. Consequently, there might be alterations in lipid
metabolism and the inflammatory process in the small intestinal mucosa.
1. Introduction
Celiac disease (CD) is a chronic immune-mediated enteropa-
thy with 1% worldwide prevalence. CD is triggered by inges-
tion of a group of proteins, commonly known as gluten, from
wheat, barley, and rye, in genetically susceptible individuals
[1, 2]. CD is a polygenic disorder and certain HLA alleles are
the most important genetic factors involved. Almost all of
the patients carry theHLA variantsHLA-DQ2 (DQA1∗05:01,
DQB1∗02:01), HLA-DQ8 (DQA1∗03, DQB1∗03:02), and
HLA-DQ2 (DQA1∗02:01, DQB1∗02:02) [3]. The role of HLA
molecules was clearly established when gluten-specific T cells
were isolated from small intestine of CDpatients at diagnosis.
These T cells are IFN𝛾 producers and are restricted to HLA-
DQ2 or HLA-DQ8molecules [3, 4].Though CD presents the
highest associationwith particularHLAalleles in comparison
with other diseases, these genes only account for 40–50%
of the genetic susceptibility. Therefore, HLA is considered a
necessary, but not a sufficient, factor for CD development.
In recent genetic studies, 39 non-HLA loci were found to be
susceptibility factors for CD [5].
CD enteropathy is commonly limited to proximal small
intestine where the characteristic histological findings are vil-
lous atrophy, crypt hyperplasia, and lymphocytic infiltration.
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These histological changes cause loss of intestinal function
and malabsorption syndrome. Mechanisms of both innate
and adaptive immunity are involved in the damage to the
small intestinal mucosa [1, 2].
Currently, CD diagnosis is based on clinical evaluation,
positive serology (anti-transglutaminase 2, anti-deamidated
gluten peptides, and anti-endomysium antibodies), and the
histological examination of a small intestine biopsy. Dietary
exclusion of gluten proteins (gluten-free diet, GFD) restores
the histology of the intestinal mucosa, reverts the symptoms,
and is considered as complementary information in the
diagnosis of CD [6]. Though serological tests present high
analytical efficiency, CD diagnosis is still based on the assess-
ment of the histology of intestinal biopsies. New noninvasive
tools for diagnosis and follow-up of CD patients are needed.
Intestinal and liver fatty acid binding protein (IFABP and
LFABP, resp.) have been reported as markers of intestinal
epithelial damage in mesenteric thrombosis, necrotizing
colitis, and celiac disease [7–10]. The fatty acid binding
protein (FABP) family comprises 9 isoforms of small cytosolic
proteins (14-15 kDa) expressed in different tissues, where
more than one type of FABP can be found [11].These proteins
bind and transport long chain fatty acids (among other
hydrophobic ligands). Specifically, IFABP and LFABP have
been suggested by in vitro studies to be involved in lipid
uptake from the intestinal lumen into the enterocyte [12, 13].
IFABP and LFABP are highly expressed in the entero-
cyte, representing 1-2% of the total cytosolic proteins [14].
Moreover, the mRNAs of IFABP and LFABP are the most
abundant translatable RNA sequences in the gut epithelium
[15]. Nevertheless, their individual functions in the intestine
have not been fully elucidated. Several lines of evidence indi-
rectly suggest they may perform different functions within
the same cell type. For example, although all the FABPs have
a highly conserved tertiary structure, containing a 10-strand
beta-barrel where ligands are bound [11, 16], IFABP binds a
single fatty acid per molecule whereas LFABP can bind up
to two fatty acids and other hydrophobic ligands [17, 18].
Fatty acid binding specificity and mechanism of transfer to
membranes are also different for IFABP and LFABP [19, 20].
Studies by immunofluorescence showed that IFABP and
LFABP are expressed in the epithelium of normal small
intestine [21]. Differentiated enterocytes abundantly express
IFABP and LFABP, and the latter is produced in 40 to 50
times higher concentration [8, 22]. Due to enterocyte damage
occurring in CD enteropathy, LFABP and IFABP are released
into peripheral blood. As a consequence, levels of LFABP
and IFABP were found significantly elevated in circulation
in untreated CD patients compared to nonceliac controls
[10, 23–25].
The putative participation of intestinal FABPs in CD
deserves further exploration for at least two main reasons.
First, other FABPs have been found to participate as medi-
ators in inflammatory processes in the tissues where they are
expressed [26–28]. Second, the alteration of the enterocyte
epithelia interferes with the absorption of nutrients and this
could lead to modifications in intracellular lipid transport,
proteins expression, and/or function.
With the aim of exploring these possibilities, after deter-
mining the serum levels of IFABP in a local population of
untreated CD patients compared to nonceliac controls, we
analyzed the expression pattern of IFABP and LFABP at
protein andmRNA levels in human small intestine in normal
and enteropathy tissues.
2. Materials and Methods
2.1. Ethics Statements. Duodenal biopsies and blood samples
were obtained from pediatric and adult patients during
routine procedures to diagnose CD at the Gastroenterology
Units of Sor Maria Ludovica Hospital and HIGA San Martin
from La Plata, Buenos Aires, Argentina, respectively. Patients
or their guardians provided a written informed consent to
participate in this study. The present study was approved by
the Ethical Committees of the Sor Maria Ludovica Hospital
and HIGA San Martin from La Plata, Argentina.
2.2. Patients and Samples. CD diagnosis was achieved by
evaluation of clinical presentation, histological examination,
and serological analysis. All pediatric and adult celiac patients
had classical presentation, with signs and symptoms of
malabsorption including chronic diarrhea, abdominal pain,
distension, and failure to thrive or weight loss. Serologi-
cal studies included determination of IgG and IgA anti-
transglutaminase 2 antibodies, IgG and IgA anti-deamidated
gluten peptides antibodies. In all the cases, positive serology
was considered when antibody levels were, at least, twice the
cut-off level.
For diagnostic purposes, three biopsy pieces were taken
from the second portion of the duodenum and evaluated by
an expert pathologist.
Altogether, this study included CD patients with total or
partial villus atrophy, classical clinical manifestations, and
positive serology.
Patients on gluten-free diet (GFD) presented histological
recovery and negative serological markers for CD. Non-
celiac individuals who suffered from other gastrointestinal
conditions, primarily dyspepsia, and presented negative CD
serology and normal duodenal histology were also included
in this study. The diagnosis of inflammatory bowel disease
was confirmed by established clinical, endoscopic, and histo-
logical criteria. In this study, samples from a pediatric patient
suffering from ulcerative colitis and six from adult patients
(4 with ulcerative colitis and 2 with Crohn’s disease) were
included. Crohn’s disease patients had no ileal involvement.
All samples of IBD patients were taken at diagnosis and they
did not receive any treatment at the time of sample collection.
Serum samples were collected from 42 nonceliac controls
(16 pediatric cases, 26 adults), 40 untreated CD patients
(17 pediatric cases, 23 adults), 9 patients on gluten-free diet
(GFD) (3 pediatric cases, 6 adults), and 7 intestinal bowel
disease (IBD) patients (1 pediatric case, 6 adults).
Duodenal samples were obtained from 27 pediatric
patients (13 nonceliac controls, 14 CD patients) and 15 adult
individuals (9 nonceliac controls, 6 CD patients). Samples
were stabilised using RNAlater (Ambion, cat. AM7020) and
stored at −80∘C until processing for gene expression analysis.
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2.3. Assessment of Serum Levels of IFABP. Determination
of IFABP serum levels was performed using an ELISA kit
(HyCult Biotech, HK406) following the instructions pro-
vided by the manufacturer. Serum samples from nonceliac
controls, treated and untreated celiac disease patients, and
IBD patients were analyzed. Values are expressed as mean ±
standard deviation (s.d.) of the mean.
2.4. Production of Anti-FABPs Polyclonal Antibodies. We ana-
lyzed the expression of human FABPs in duodenal samples
using rabbit polyclonal antibodies raised against rat FABPs.
Sequence and structure of rat and human FABPs have been
well established. The 132-residue rat and human IFABPs
have 82% amino acids’ sequence identity [29] leading to a
high degree of homology (83%) and cross-reactivity between
human and rat LFABP [30]. Recombinant rat IFABP and
LFABPwere produced in E. coli BL21 (DE3) cells transformed
pET11d-IFABP, pET11a-LFABP and purified as described
elsewhere [20, 31], performing exclusion chromatography
(Sephadex G-50, Pharmacia Biotech Inc.), followed by
anion exchange chromatography (DE-52, Whatman) and
finally delipidation using a Lipidex-1000 column. SDS-PAGE
electrophoresis followed by Coomassie Brilliant Blue R250
(Thermo Scientific) staining was used to assess FABP purity.
Purified IFABP and LFABP were used to immunize rabbits
according to the standard protocol [32]. Reactivity of poly-
clonal antibodies from immunized rabbits was assessed by
western blotting and ELISA using the recombinant proteins.
Western blot was developed using a chemiluminescent HRP
substrate (Thermo, cat. 34080).
2.5. Analysis of IFABP and LFABP Expression in Small Intes-
tine. Sections of paraffin-embedded small intestine biopsies
were obtained using a Leica SM 2000R microtome; subse-
quently they were rehydrated and Citra solution (Biogenex,
cat. HK086-9K) was used for antigen retrieval. Sections
were stained with anti-IFABP or anti-LFABP rabbit poly-
clonal antibodies (dilutions used: LFABP 1/200–1/400, IFABP
1/20–1/50). Afterwards, they were incubated with anti-rabbit
IgG conjugated with Alexa 488 (Life Technologies, cat. A-
21206). Nuclei were stained with propidium iodide or DAPI.
Confocal fluorescence microscopy analysis was performed
in a SP5 Leica confocal microscope. Immunofluorescence
analysis was performed in a Nikon Eclipse E400 fluorescence
microscope.
2.6. Quantitative PCR Analysis. Total RNA was isolated
from whole biopsy samples using an RNA Spin Mini kit
(GE Healthcare, cat. 25-0500-72). Reverse transcription was
performed using 1 𝜇g of total RNA. MML-V polymerase
and random primers were obtained from Molecular
Probes Inc., Invitrogen (Carlsbad, CA, USA). Quantitative
Real Time PCR was performed in an IQ Cycler from
BioRad using SYBR green mix (Invitrogen, cat. 11761-
100) and specific primers for the genes of interest:
IFABP forward AGCACTTGGAAGGTAGACCG, IFABP
reverse CCCCTGAGTTCAGTTCCGTC; LFABP forward
AGCTCTATTGCCACCATGAGTTTCT, LFABP reverse
AACTGAACCACTGTCTTGACTTTCTC; 𝛽-actin forward
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Figure 1: Increased levels of IFABP in serum samples of active CD.
IFABP serum levels (pg/mL) were assessed by commercial quantita-
tive ELISA. Serum samples from adults and pediatric patients were
plotted together since no differences between both populations were
observed. Serum samples from controls (𝑛 = 42), untreated CD
patients (𝑛 = 40), CD patients on gluten-free diet (GFD) (𝑛 = 9),
and intestinal bowel disease (IBD) patients (𝑛 = 7) were analyzed.
Values are expressed as mean ± standard deviation (s.d.) of the
mean. Representative experiments were analyzed statistically using
the Mann-Whitney 𝑈 test. (A) 𝑝 < 0.0001; (B) 𝑝 = 0.0002; (C)
𝑝 = 0.0264.
ATGGGTCAGAAGTCCTATGTG, 𝛽-actin reverse
CTTCATGAGGTAGTCAGTCAGGTC; villin forward
CTACACCACACAGATGGATGACTTC, villin reverse
GACATCTCTACCTCTCCAGCTACCA. The comparative
Ct method was used to quantify IFABP and LFABP tran-
scripts normalizing alternatively with𝛽-actin or villin. Values
are expressed asmean± standard deviation (s.d.) of themean.
2.7. Statistical Analysis. Both statistical evaluation of serum
levels of IFABP by ELISA and quantitative PCR analysis
of IFABP and LFABP mRNA levels were performed by the
Mann-Whitney 𝑈 test.
3. Results
3.1. IFABP Serum Levels. The concentration of IFABP in
serum samples was determined by a commercial quantita-
tive ELISA kit. Untreated CD patients presented significant
higher levels of IFABP in serum compared to treated CD
patients, non-CDcontrols, or IBDpatients. Because therewas
no difference between samples from pediatric and adult pop-
ulations, the results obtained from both populations were
depicted together.No differenceswere found between non-CD
controls, CD patients on GFD, and IBD patients (Figure 1).
The assessment of IFABP concentration in serum samples
showed statistical differences for samples from CD patients
at diagnosis (mean value 2898.89 pg/mL, range 616.83–
7295.95 pg/mL), non-CDcontrols (mean value 1356.49 pg/mL,
range 256.51–3433.33 pg/mL), CD patients on GFD (mean
value 1766.84 pg/mL, range 391.42–3955.88 pg/mL), and
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Figure 2: Assessment of reactivity of the rabbit polyclonal antibodies. Western blot analysis was performed using recombinant purified
LFABP (protein loaded: 0.25–2 𝜇g) and IFABP (protein loaded: 0.25–2 𝜇g). Rabbit anti-LFABP and anti-IFABP polyclonal antibodies were
incubated at 1/6000 and 1/20000 dilutions, respectively.
IBD patients (mean value 744.92 pg/mL, range 165.89–
1558.2 pg/mL).
Serum IFABP levels might serve to discriminate CD
patients from non-CD controls as described by previous
reports [10, 23–25].
Similar IFABP levels in serum from patients on GFD and
controls were observed, suggesting that IFABP may also be a
biomarker to follow up the response to treatment. Remarka-
bly, IFABP concentration in serum samples from IBDpatients
was similar to the values observed in non-CD controls.These
results suggest that the increase of IFABP concentration in
serum is a specific finding inCDenteropathy, which is limited
to the proximal small intestine.
3.2. Expression of LFABP and IFABP in Human Duodenum.
In order to evaluate the expression pattern of LFABP and
IFABP in human duodenum by immunofluorescence tech-
niques, rabbit polyclonal antibodies were raised by inocu-
lating purified recombinant rat IFABP or LFABP. Western
blot analysis showed that each of the polyclonal antibod-
ies produced in our laboratory specifically reacts with the
protein used as antigen. No cross-reactivity was observed
between IFABP and LFABP (Figure 2). These antibodies
proved to be useful for detecting human IFABP and LFABP.
This reactivity is based on the homology of these human
and rat FABPs. Specific labeling was verified on duodenal
sections from healthy control and enteropathy samples using
serum from an unimmunized rabbit (see Supplementary
Figure 1 in the Supplementary Material available online at
http://dx.doi.org/10.1155/2015/738563).
The expression of LFABP was analyzed in sections of
duodenal biopsies from healthy controls and CD patients at
diagnosis. Conventional indirect immunofluorescence analy-
sis showed that LFABP is abundantly expressed in enterocytes
from the villi but not in the crypts in healthy tissue (Figures
3(a) and 3(b)). In duodenal samples fromCDpatients LFABP
was observed in enterocytes and remarkably in the crypts
(Figure 3(c)). LFABP expression was more intense in the
crypts closer to the epithelium fading away towards the
muscularis mucosae. Similar findings were observed by flu-
orescence confocal microscopy (Figures 3(d) and 3(e)). Fully
differentiated enterocytes showed homogeneous cytoplasmic
staining for LFABP in the epithelium from tissues of both
non-CD controls and CD patients. Crypts closer to the
epithelium were also stained in severe enteropathy (Figures
3(c) and 3(f)).
The analysis of IFABP expression by conventional
immunofluorescence microscopy showed bright staining in
enterocytes but also very faint staining in some crypts of small
intestine from nonceliac controls (Figures 4(a) and 4(b)).
Enterocytes in the remaining epithelium and in the crypts
were strongly stained in duodenal samples from CD patients
at diagnosis (Figure 4(c)). Confocal fluorescence microscopy
analysis showed homogeneous staining for IFABP in the
enterocytes in healthy small intestine (Figures 4(d) and
4(e)). IFABP expression was observed in enterocytes in the
damaged epithelium as well as the crypts in small intestine of
untreated CD patients (Figure 4(f)).
3.3. LFABP and IFABP mRNA Levels in Small Intestine.
The expression of LFABP and IFABP mRNA in duodenal
tissue was assessed by quantitative PCR using 𝛽-actin as
housekeeping gene.
In non-CD controls, highermRNA levels for both LFABP
and IFABP were observed in adult than in pediatric small
intestine (Figure 5). mRNA levels of LFABP were higher
than those of IFABP. Strikingly, the expression of LFABP and
IFABP was lower in untreated adult CD patients compared
with non-CD controls. This difference was not observed in
pediatric population.
FABPs’ expression pattern, previously observed by immun-
ofluorescence studies, suggests that an intense synthesis
process occurs in fully differentiated enterocytes located in
the villi. In severe enteropathy, these FABPs are also produced
in the crypt enterocytes. However, a reduction in the mRNA
levels in tissues showing severe enteropathy was observed.
The small intestine in untreated CD patients shows
relevant histological changes, particularly loss of epithelium
and enlargement of lamina propria. These changes can be
described as a reduction in the ratio of number of cells from
epithelium versus cells from lamina propria. To estimate this
variation, we focused our attention on the expression of villin,
which is limited to differentiated enterocytes. Thus, the use
of villin as housekeeping gene allows a better evaluation of
changes in mRNA levels of proteins specifically expressed
in the enterocytes [33]. As expected, the severe histological
alterations observed in severe enteropathywere accompanied
by changes at mRNA levels of villin compared with 𝛽-
actin. VillinmRNA levels were reduced in severe enteropathy
compared with normal tissue (Figure 6(a)).
Therefore, we decided to use villin as housekeeping gene
to reevaluate the changes in the expression of FABPs in duo-
denal samples. We found that mRNA levels of both LFABP
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Figure 3: LFABP expression in human small intestine. Indirect immunofluorescence analysis using anti-LFABP polyclonal antibodies (Alexa
488, green) and nuclei stained with DAPI (blue). Representative staining in duodenal sections of non-CD control ((a) and (b)) and CD
patient at diagnosis (c) (magnification 20x). Confocal fluorescence microscopy using anti-LFABP polyclonal antibodies (Alexa 488, green)
and nuclei stained with propidium iodide (red). Representative staining in duodenal sections of non-CD control ((d) and (e)) and CD patient
at diagnosis (f) (magnification 63x + 1.7 zoom). Healthy tissue ((a), (b), (d), and (e)) shows LFABP expression in the villi enterocytes. Severe
enteropathy ((c) and (f)) shows LFABP expression in the epithelium as well as the crypts closer to the epithelium.
and IFABP were higher in samples with severe enteropa-
thy compared with healthy tissue when villin was used as
housekeeping gene, though a significant difference was only
observed for IFABP. LFABP mRNA levels were higher than
IFABP mRNA levels as described above (Figure 6(b)).
Altogether, these results indicate that in CD FABPs
expression is actually increased inside enterocytes (signifi-
cantly for IFABP) although theirmRNA levels are lowerwhen
evaluating the whole intestinal sample due to the reduction of
enterocyte to lamina propria cells ratio.
4. Discussion
CD is an immune-mediated enteropathy triggered by dietary
gluten peptides in genetically susceptible individuals. The
histological findings range from increasednumber of intraep-
ithelial lymphocytes and a minor reduction in the villus
height/crypt depth ratio up to total villus atrophy.The mech-
anism of mucosal damage is still not completely understood
[2, 3].
Clinical evaluation, serology, and histology determine the
diagnosis of CD. However, diagnosis cannot be established
in some cases due to the lack of concordance between
serology and histology [34, 35]. In addition,minor changes in
the histology are frequently referred to as unspecific findings.
Thus, a large number of cases may remain undiagnosed [36,
37]. HLA typing by identifying the presence of the HLA class
II susceptibility alleles (HLA-DQ2/DQ8) is a complementary
test with high negative predictive value and is useful as
exclusion criteria. However, the high cost of this technique
precludes its use in the routine clinical practice.
Noninvasive tests using markers for intestinal permeabil-
ity have been used to evaluate the integrity of the gut mucosa
[38, 39]. However, these tests are unspecific because many
different conditions alter intestinal permeability. There is a
current need for new tests for the identification of absorption
alterations in the intestinal mucosa [40]. Thus, the search
for noninvasive tests based on the evaluation of biomarkers
that specifically detect CD or characterize its active stage is a
promising tool for screening strategies, complementary infor-
mation when diagnosis is controversial, or treatment follow-
up. We recently showed that the inflammatory chemokine
CXCL10 is abundantly produced in duodenal mucosa in
untreated celiac patients, and also significant higher levels
of circulating CXCL10 were found in untreated CD patients.
Concentration of CXCL10 in serum returns to basal levels
in patients on gluten-free diet. Though further studies eval-
uating large number of samples are required, these findings
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(a) (b) (c)
(d) (e) (f)
Figure 4: IFABP expression in human small intestine. Indirect immunofluorescence analysis using anti-IFABP polyclonal antibodies (Alexa
488, green) and nuclei stained with DAPI (blue). Representative staining in duodenal sections of non-CD control ((a) and (b)) and CDpatient
at diagnosis (c) (magnification 20x). Confocal fluorescence microscopy using anti-IFABP polyclonal antibodies (Alexa 488, green) and nuclei
stainedwith propidium iodide (red). Representative staining in duodenal sections of non-CD control ((d) and (e)) andCDpatient at diagnosis
(f) (magnification 63x + 1.7 zoom). Healthy tissue ((a), (b), (d), and (e)) shows IFABP expression in the villi enterocytes. Severe enteropathy
((c) and (f)) shows IFABP expression in the epithelium as well as the crypts.
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Figure 5: mRNA levels of LFABP and IFABP assessed by quantitative PCR using 𝛽-actin as housekeeping gene. Quantitative PCR analysis
was performed in whole duodenal biopsies from adult and pediatric populations of healthy non-CD controls and CD patients at diagnosis.
Pediatric samples: controls (𝑛 = 13), CD patients (𝑛 = 14). Adult samples: controls (𝑛 = 9 for IFABP, 𝑛 = 8 for LFABP), CD patients (𝑛 = 6).
Results were plotted as relative unit (RU), using 𝛽-actin as housekeeping gene. Values are expressed as mean ± standard deviation (s.d.) of
the mean. Representative experiments were analyzed statistically using the Mann-Whitney 𝑈 test. (A) 𝑝 = 0.0047; (B) 𝑝 = 0.0423; (C, D)
𝑝 < 0.0001.
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Figure 6: mRNA levels assessed by quantitative PCR of (a) villin using 𝛽-actin as housekeeping gene and (b) LFABP and IFABP using
villin as housekeeping gene. Quantitative PCR analysis was performed in whole duodenal biopsies from adult and pediatric populations of
healthy non-CD controls and CD patients at diagnosis. mRNA relative levels from adults and pediatric patients were plotted together since
no differences between both populations were observed. (a) mRNA levels of villin using 𝛽-actin as housekeeping gene. Pediatric samples:
controls (𝑛 = 10), CD patients (𝑛 = 9). Adult samples: controls (𝑛 = 8), CD patients (𝑛 = 6). (b) mRNA levels of LFABP and IFABP using
villin as housekeeping gene. Pediatric samples: controls (𝑛 = 12), CD patients (𝑛 = 13). Adult samples: controls (𝑛 = 8), CD patients (𝑛 = 6).
Results were plotted as relative unit (RU). Values are expressed as mean ± standard deviation (s.d.) of the mean. Representative experiments
were analyzed statistically using the Mann-Whitney 𝑈 test. (A) 𝑝 = 0.0374; (B) 𝑝 = 0.0294.
point to CXCL10 as a biomarker for the evaluation of CD [41].
Additionally, there are new proposed biomarkers of intestinal
epithelial cell damage such as Reg-3𝛼 [42].
Enterocyte FABPs are proposed for binding and traf-
ficking long chain fatty acids absorbed from the dietary
lipids to different cell fates ranging from mitochondrial beta
oxidation, regulation of gene expression in the nuclei, and
chylomicron synthesis, among others [43].Thus, it is possible
to assume that in malabsorption syndromes, such as CD,
these proteins may play a relevant role.
The measurement of cytosolic enterocyte proteins in
peripheral blood has also been shown to be useful for esti-
mating enterocyte damage [22]. IFABP and LFABP are highly
expressed in enterocytes [21]. IFABP has also been proposed
as a differentiation marker to evaluate intestinal maturation
in preterm neonates [44]. Enterocytes on the top of the villi
are the initial site of cell destruction in numerous intestinal
diseases.Thus, high serum levels of FABPsmay correlate with
a higher rate of enterocyte damage. Serum IFABPwas used as
a biomarker to detect active CD. Since it is highly expressed
in the villi tip, Vreugdenhil et al. [24] proposed IFABP as an
early marker of intestinal damage in CD. In addition, as the
expression of IFABP is limited to the intestinal epithelium,
this protein is a better marker of intestinal damage than
LFABP which is also expressed in other tissues [10]. The
concentration of IFABP in serum samples also correlates
with both anti-transglutaminase 2 IgA antibody levels and the
severity of villous atrophy in CD patients at the time of diag-
nosis [23–25]. In addition, IFABP determinationmay have an
advantage over anti-TG2 given that IFABP’s half-life is shorter
and could reflect rapid changes atmucosal level. IFABP values
diminished to normalization in CD patients after GFD for
at least a year, independently of initial antibodies and IFABP
levels. Nevertheless, all the studies mentioned above reported
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the use of different cut-off values for IFABP levels in plasma.
Therefore, with the aim of using the determination of serum
IFABP in clinical practice, studies involving a large number
of samples and validated procedures are needed.
Similarly to reported studies, in this work we observed
higher concentrations of IFABP in serum samples of CD
patients at the time of diagnosis compared to samples from
patients onGFD or controls.Thus, the analysis of a local pop-
ulation replicated previous reports [10, 23–25] and showed
that determination of the concentration of IFABP in serum
may be used as a noninvasive test in diagnosis and GFD
follow-up. In addition, our pilot study showed significantly
higher IFABP levels in serum of CD patients compared to
samples from IBD patients suggesting the potentiality of
IFABP as a biomarker which may help in clinical practice to
discriminate between samples from CD and IBD patients. To
this end, further evaluation using a large number of cases is
needed.
The use of circulating IFABP as a specific biomarker of
small intestinal enterocytes damage was also suggested by
Wiercinska-Drapalo et al. [45]. Authors found high levels of
IFABP in serum from a group of ulcerative colitis patients
suffering from ileitis, an extended inflammatory process in
the terminal small intestine. This finding was associated with
a diagnostic value of serum IFABP released from damaged
enterocytes of the terminal small intestine.
In addition, analysis of IFABP urinary levels has been
proposed as predictive biomarker of necrotising enterocolitis.
Detection of IFABP in urine samples, as a consequence of
its release from small intestine enterocytes, is useful for
diagnosis since it may anticipate the rapid progression of this
disease [46].
In agreement with a previous report [21], in this work
we observed that LFABP and IFABP are highly expressed in
the enterocytes of small intestine in healthy tissue. However,
some differences in the pattern of expression were evidenced.
Whereas Levy et al. [21] described expression of LFABP and
IFABP in the crypts, we observed no staining for LFABP and
a very faint staining for IFABP in the crypts from proximal
duodenum.These differences are probably due to differences
in the immunofluorescence techniques used, mainly the
quality of the images obtained, and secondly the intestinal
segments investigated in each study.
Our work revealed an important change in the expression
of both FABPs when samples with severe enteropathy were
analyzed. Remarkably, an intense crypt staining for both
FABPs was observed. The staining for LFABP was more
intense in crypts located close to the epithelium whereas
IFABP showed an intense staining in all crypts, close to and
far away from the remaining epithelium.Thiswas a character-
istic finding in tissues showing severe enteropathy from CD
patients at the time of diagnosis. To our knowledge, this is the
first description of this change in FABPs’ expression pattern.
The increased expression of FABPs in the immature entero-
cytes in the crypts may reflect an accelerated developmental
program of enterocytes. Highly differentiated enterocytes
are unable to replace the lost epithelia as a consequence
of the extended damage process. Therefore, LFABP and
IFABP, which are normally expressed in fully differentiated
enterocytes from the small intestine, may appear earlier in
the crypt enterocytes due to a faster developmental program.
Next, we evaluated the mRNA expression of LFABP and
IFABP in small intestine using 𝛽-actin as housekeeping gene.
Higher expression of both LFABP and IFABP was observed
in control adult small intestine compared to control pediatric
samples (Figure 5). By western blot analysis, Levy et al. [21]
did not observe changes in the expression of FABPs at protein
level in normal pediatric and adult jejunum. However, a
quantitative analysis was not performed in this study.
Strikingly, the analysis of samples from adult CD patients
at the time of diagnosis showed a significant reduction in
the mRNA levels of LFABP and IFABP compared to healthy
tissue. On the other hand, pediatric samples showed no
difference in mRNA levels between CD patients and control
for either protein (Figure 5).
Since qPCR results are expressed as a ratio of the
transcript of interest and the housekeeping gene on the
whole piece of tissue, the reduction of LFABP and IFABP
mRNA levels observed in adult CD patients is likely due
to histological changes. Healthy tissue contains a long layer
of epithelial cells and a limited lamina propria, whereas in
severe enteropathy it is just the opposite, a reduced epithelial
layer and a larger lamina propria. Consequently, to evaluate
whether the change in the histology may explain the results
obtained, we used villin as housekeeping gene. It is worth
noting that villin specificity is such that its promoter has been
used for transgenic expression of different proteins limited to
the enterocyte [47]. The epithelium loss in duodenal samples
from untreated CD patients was accompanied by a reduction
in the relative expression of villin.The analysis of LFABP and
IFABP mRNA expression using villin as housekeeping gene
showed higher levels of LFABP and IFABP transcripts in CD
samples compared to non-CD controls, reaching statistical
significance for IFABP (Figure 6). This would be suggesting
an upregulation in FABPs expression within the enterocytes,
as described in the renal ischemic injury for LFABP [48].
Taken together, we observed that the expression of LFABP
and IFABP is limited to fully differentiated enterocytes in
healthy tissue whereas in active CD they are also expressed
in immature enterocytes from the crypts. Though the mRNA
analysis using villin as housekeeping gene showed that FABPs
expression is increasedwithin enterocytes in CD enteropathy,
the total expression in the tissue, referred to 𝛽-actin, was
diminished. In accordance with these findings, Simula et al.
[49], using quantitative proteomic analysis, found lower lev-
els of LFABP (FABP1) and IFABP (FABP2) in duodenal sam-
ples from active CD patients compared to healthy small intes-
tine, using vinculin as normalizing protein. Considering the
multiple biological roles of FABPs in the intestinal mucosa,
the lower expression of FABPs may have pathological effects.
One of the possible mechanisms involved is through the
PPAR𝛾 signaling pathway. PPAR𝛾 is a ligand-activated
nuclear receptor which plays multiple roles in metabolism,
cellular proliferation, differentiation, and immune response
[50]. Particularly, PPAR𝛾 performs relevant biological func-
tions in the intestinal mucosa, where it also contributes to
anti-inflammatory and regulatory effects [51].The interaction
of LFABPwith PPAR𝛼 andPPAR𝛾has already been described
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in hepatocytes [52], and LFABP’s function as a mediator in
PPAR activity in the nucleus has been shown. Taking this
into account, we can hypothesize that LFABP and IFABP
may modulate the function of PPAR𝛾 in enterocytes, and
thus changes in FABPs expression may affect PPAR𝛾 acti-
vation. Interestingly, downregulation of FABPs and PPAR𝛾
was found in small intestine of CD patients [49], which
may explain some of the alterations observed in signaling
pathways in active CD. LFABP and IFABP knock-out mice
have shown alterations inmucosal lipidmetabolism, with dif-
ferential lipid assimilation in each knock-out type [53]. In this
context, it is possible to speculate that lipid metabolism may
be altered in this pathology as well. Further studies will be
carried out to asses this hypothesis. In this work, we showed
changes in the pattern of expression of LFABP and IFABP in
proximal small intestine in severe enteropathy.These changes
are likely associated with the histological changes observed in
the intestinal mucosa in active CD and alterations in entero-
cyte differentiation. In conclusion, these findings suggest that
changes in FABPs expressionmay have a relevant influence in
the control of the immune response aswell as other important
functions in the intestinalmucosa, which altogethermay con-
tribute to the pathogenic mechanism of damage in active CD.
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